Q1 25 EPS
$6.74
BEAT +6.17%
Est. $6.35
Q1 25 Revenue
$65.50B
BEAT +8.48%
Est. $60.38B
vs S&P Since Q1 25
-41.0%
TRAILING MARKET
CI -13.9% vs S&P +27.2%
Market Reaction
Did CI Beat Earnings? Q1 2025 Results
The Cigna Group delivered a standout first quarter for 2025, posting earnings per share of $6.74 against a consensus estimate of $6.35, a beat of 6.17%, while revenue of $65.50 billion cleared expectations by 8.48% and grew 14.4% year-over-year. The … Read more The Cigna Group delivered a standout first quarter for 2025, posting earnings per share of $6.74 against a consensus estimate of $6.35, a beat of 6.17%, while revenue of $65.50 billion cleared expectations by 8.48% and grew 14.4% year-over-year. The primary engine behind that top-line surge was Evernorth Health Services, where specialty pharmacy momentum and expanding client relationships drove adjusted revenues 16% higher, with specialty and care services alone climbing 19% on strong biosimilar adoption. Cigna also completed the divestiture of its Medicare businesses to Health Care Services Corporation in March, a transaction that reshaped the portfolio and contributed to a higher medical care ratio of 82.2%, though management views the underlying commercial business as fundamentally sound. The strong results arrive at a telling moment for the sector, as peers have struggled with elevated medical costs, lending Cigna's performance added significance. Reflecting that confidence, the company raised its full-year 2025 adjusted income outlook to at least $29.60 per share, up $0.10 from prior guidance.
Key Takeaways
- • Growth of existing client relationships in Evernorth Health Services
- • Strong specialty pharmacy volume growth including increased Humira biosimilar adoption
- • Premium rate increases to cover expected increases in underlying medical costs in Cigna Healthcare
- • Lower adjusted SG&A expense ratio driven by strong revenue growth and business mix shift
- • Completion of Medicare business divestiture to HCSC on March 19, 2025
CI YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
CI Revenue by Segment
With YoY comparisons, source: SEC Filings
“We are building a more sustainable health care model by successfully delivering on our series of commitments and actions to improve transparency and support for our customers and patients.”
— David M. Cordani, Q1 2025 Earnings Press Release
CI Earnings Trends
CI vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CI EPS Trend
Earnings per share: estimate vs actual
CI Revenue Trend
Quarterly revenue: estimate vs actual
CI Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $7.79 | — | $68.49B | — |
| Q4 25 BEAT FY | $7.65 | $8.08 | +5.65% | $72.47B | +9.17% |
| FY Full Year | — | $29.84 | — | $274.90B | — |
| Q3 25 BEAT | $7.64 | $7.83 | +2.47% | $69.75B | +4.50% |
| Q2 25 BEAT | $7.15 | $7.20 | +0.65% | $67.18B | +7.30% |
| Q1 25 BEAT | $6.35 | $6.74 | +6.17% | $65.50B | +8.48% |